Welcome to our dedicated page for GeneDx Holdings SEC filings (Ticker: WGS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
GeneDx Holdings Corp.'s filings document financial results and operating disclosures for a genomics diagnostics company focused on rare disease testing. Form 8-K reports furnish quarterly and annual results, earnings presentations, preliminary revenue and testing-volume guidance, changes in statement presentation, and modifications to non-GAAP financial measure methodology.
The filing record also covers capital structure and governance matters, including a term loan agreement used to refinance existing debt, Class A common stock and Nasdaq-listed warrant disclosures, board composition changes, and definitive proxy materials. Proxy filings describe director elections, executive compensation, equity awards, stockholder voting matters, and related corporate governance policies.
GeneDx Holdings Corp. is holding its 2026 virtual annual meeting on June 18, 2026 to elect one Class II director, ratify Ernst & Young LLP as auditor, and conduct advisory votes on executive compensation and its voting frequency. The Board supports electing CEO Katherine Stueland as Class II director, ratifying Ernst & Young, approving executive pay, and holding say‑on‑pay votes every year.
The proxy highlights 2025 performance, including revenue of $427.5 million, 41% year‑over‑year growth, exome and genome test revenue of $360.3 million, adjusted gross margin of 71%, and adjusted net income of $41.8 million. Executive pay is structured around base salary, annual cash incentives, and equity awards, with increased use of performance‑based RSUs and new stock ownership and clawback policies.
WGS reported proposed dispositions of Class A Common Stock by an affiliate under Form 144. The filing lists restricted stock units acquired on 05/02/2022 (392 shares), 09/01/2022 (374 shares), 12/09/2022 (1,284 shares) and 04/26/2023 (3,754 shares). The Form 144 shows multiple sales reported during early 2026, including 317 shares on 01/29/2026, 287 shares on 03/02/2026, 6,187 shares on 03/04/2026, 1,280 shares on 03/09/2026, 5,706 shares on 03/16/2026, and 8,818 shares on 03/26/2026. The filing identifies Morgan Stanley Smith Barney as broker and lists NASDAQ as the market.
WGS affiliate reported proposed sales of Class A common stock under Form 144. The filing lists multiple RSU-derived share lots and a series of sales by Katherine Stueland, with individual sale quantities and post-transaction holdings shown for dates in 2026.
The notice records sale dates and share counts; timing and placement details beyond the listed dates are not included.
GeneDx Holdings Corp. chief financial officer Kevin Feeley reported routine equity compensation activity. He exercised 16,250 restricted stock units, receiving the same number of Class A Common Stock shares for no cash cost. On the same date, he sold 8,818 shares of Class A Common Stock in several open-market transactions at weighted average prices in the low-to-mid $60s per share. According to the disclosure, these sales were executed solely to cover tax withholding obligations from the RSU vesting under a “sell to cover” arrangement and were not discretionary trades. After these transactions, he beneficially owned 34,580 shares of Class A Common Stock, plus RSUs representing contingent rights to receive up to 93,173 additional shares and options to purchase up to 25,906 shares, all vesting over time according to their terms.
GeneDx Holdings Corp. CEO Katherine Stueland exercised 80,000 restricted stock units into Class A common stock and had 46,933 shares sold to cover tax withholding obligations. The sales were executed as non-discretionary “sell to cover” transactions at weighted average prices between approximately $60.93 and $65.61 per share.
After these transactions, she beneficially owned 91,514 shares of Class A common stock and also held restricted stock units representing contingent rights to receive up to 334,695 additional shares, plus options to purchase up to 107,610 shares that vest according to their terms.
GeneDx Holdings Corp.'s chief executive officer Katherine Stueland reported routine equity compensation activity involving restricted stock units and related tax sales. She exercised RSUs covering 30,671 shares of Class A Common Stock at no cost as tranches vested on March 15–16. To cover tax withholding obligations from these vestings, she sold 17,179 shares in open-market transactions at weighted average prices in ranges around $75.74 to $78.16 per share pursuant to a sell-to-cover arrangement, which the filing notes was not a discretionary transaction. Following these tax-related sales, she directly owned 58,447 shares of Class A Common Stock and held RSUs representing up to 414,695 additional shares and options to purchase 107,610 shares, all vesting according to their existing terms.
GeneDx Holdings Corp. Chief Financial Officer Kevin Feeley reported routine equity compensation activity. On March 15–16, 2026, he exercised restricted stock units that converted into a total of 11,012 shares of Class A Common Stock at no cost.
On March 16, he then sold 5,706 shares of Class A Common Stock in multiple open-market transactions at weighted average prices in the mid‑$70s. According to the disclosure, these sales were made solely to cover tax withholding obligations under a “sell to cover” arrangement and were not discretionary.
After these transactions, Feeley beneficially owned 27,148 shares of Class A Common Stock and also held RSUs for up to 109,423 shares and options for up to 25,906 shares, all vesting according to their existing schedules.
GeneDx Holdings Corp. chief financial officer Kevin Feeley reported routine equity compensation activity. On March 9, 2026, he exercised restricted stock units for 2,462 shares of Class A common stock at no cost, converting RSUs into shares. He then sold 1,280 shares at a weighted average price of $86.754 per share in a "sell to cover" transaction to satisfy tax withholding obligations, which the footnotes state was not a discretionary trade. Following these moves, he directly owned 21,842 shares of Class A common stock and also held RSUs covering up to 120,435 additional shares and options for up to 25,906 shares, all vesting under their existing schedules.
GeneDx Holdings Corp. CEO Katherine Stueland reported routine equity compensation activity. She exercised restricted stock units into 6,546 shares of Class A Common Stock at no cost, then sold 3,678 of those shares at a weighted average price of $86.748 per share solely to cover tax withholding obligations via a “sell to cover” transaction, which the filing states was not discretionary.
After these transactions, she directly owned 44,955 shares of Class A Common Stock. The filing also notes additional unvested awards: RSUs representing contingent rights to receive up to 445,366 shares and options to purchase up to 107,610 shares, which vest over time according to their terms.
GeneDx Holdings Corp. chief financial officer Kevin Feeley acquired additional company stock in an insider transaction. On March 6, 2026, he obtained 1,986 shares of GeneDx Class A common stock directly from the company at $88.11 per share under a subscription agreement exempt under Rule 16b-3(d). After this award, his direct ownership increased to 20,660 shares of Class A common stock.